{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T06:27:46Z","timestamp":1782628066815,"version":"3.54.5"},"reference-count":136,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Oral and injectable drug administration have recently been replaced with transdermal\ndrug delivery (TDD) approaches, which are less intrusive, less likely to be rejected by patients,\nand easier to administer. There is still room for improvement in the treatment of gout with the use\nof a TDD system. Gout has become a worldwide epidemic and a severe threat to human beings.\nGout treatment can be accomplished in various ways, including orally and intravenously. Several\ntraditional options are still useless, cumbersome, and potentially dangerous. Hence, gout therapeutic\noptions are desperately required for more effective and less toxic drug delivery methods. Antigout\nmedications using TDD could substantially influence obese people in the future, even if most\ntrials are still in the animal stages. Thus, this review aimed to provide a concise overview of recent\nTDD technologies and anti-gout medication delivery methods that improved therapeutic efficacy\nand bioavailability. Moreover, clinical updates on investigational drugs have been discussed to\naddress the potential findings against gout.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201024666230606143827","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T07:37:37Z","timestamp":1686123457000},"page":"159-178","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Recent Updates on Transdermal Drug Delivery Approaches for the\nManagement of Gout and its Clinical Perspective"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-5265","authenticated-orcid":true,"given":"Ranjit K.","family":"Harwansh","sequence":"first","affiliation":[{"name":"Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Mishra","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India"},{"name":"Institute of Pharmacy, Noida Institute\nof Engineering and Technology, Greater Noida, 201310, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Mazumder","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy, Noida Institute\nof Engineering and Technology, Greater Noida, 201310, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohitas","family":"Deshmukh","sequence":"additional","affiliation":[{"name":"Institute of Pharmaceutical Research, GLA University, Mathura, 281406, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhlaquer","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy,\nTaif University, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"Singh J.A.","year":"2020","unstructured":"Singh J.A.; Gaffo A.; Gout epidemiology and comorbidities. Semin Arthritis Rheum 2020,50(3),S11-S16","journal-title":"Semin Arthritis Rheum"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrrheum.2017.126","volume":"13","author":"Dalbeth N.","year":"2017","unstructured":"Dalbeth N.; Bardin T.; Doherty M.; Liot\u00e9 F.; Richette P.; Saag K.G.; So A.K.; Stamp L.K.; Choi H.K.; Terkeltaub R.; Discordant American College of Physicians and international rheumatology guidelines for gout management: Consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol 2017,13(9),561-568","journal-title":"Nat Rev Rheumatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.7326\/0003-4819-54-3-452","volume":"54","author":"McCarty D.J.","year":"1961","unstructured":"McCarty D.J.; Hollander J.L.; Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961,54(3),452-460","journal-title":"Ann Intern Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"FitzGerald J.D.","year":"2020","unstructured":"FitzGerald J.D.; Dalbeth N.; Mikuls T.; Brignardello-Petersen R.; Guyatt G.; Abeles A.M.; Gelber A.C.; Harrold L.R.; Khanna D.; King C.; Levy G.; Libbey C.; Mount D.; Pillinger M.H.; Rosenthal A.; Singh J.A.; Sims J.E.; Smith B.J.; Wenger N.S.; Bae S.S.; Danve A.; Khanna P.P.; Kim S.C.; Lenert A.; Poon S.; Qasim A.; Sehra S.T.; Sharma T.S.K.; Toprover M.; Turgunbaev M.; Zeng L.; Zhang M.A.; Turner A.S.; Neogi T.; 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol 2020,72(6),879-895","journal-title":"Arthritis Rheumatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"Kuo C.F.","year":"2015","unstructured":"Kuo C.F.; Grainge M.J.; Mallen C.; Zhang W.; Doherty M.; Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann Rheum Dis 2015,74(4),661-667","journal-title":"Ann Rheum Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.200113","volume":"48","author":"te Kampe R.","year":"2021","unstructured":"te Kampe R.; Janssen M.; van Durme C.; Jansen T.L.; Boonen A.; Sex differences in the clinical profile among patients with Gout: Cross-sectional analyses of an observational study. J Rheumatol 2021,48(2),286-292","journal-title":"J Rheumatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12891-017-1465-9","volume":"18","author":"Harrold L.R.","year":"2017","unstructured":"Harrold L.R.; Etzel C.J.; Gibofsky A.; Kremer J.M.; Pillinger M.H.; Saag K.G.; Schlesinger N.; Terkeltaub R.; Cox V.; Greenberg J.D.; Sex differences in gout characteristics: Tailoring care for women and men. BMC Musculoskelet Disord 2017,18(1),108","journal-title":"BMC Musculoskelet Disord"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/ard.2009.109884","volume":"69","author":"Hak A.E.","year":"2010","unstructured":"Hak A.E.; Curhan G.C.; Grodstein F.; Choi H.K.; Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis 2010,69(7),1305-1309","journal-title":"Ann Rheum Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s10067-020-04994-9","volume":"39","author":"Roman Y.","year":"2020","unstructured":"Roman Y.; Tiirikainen M.; Prom-Wormley E.; The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. Clin Rheumatol 2020,39(8),2387-2392","journal-title":"Clin Rheumatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/AJP.0000000000000334","volume":"32","author":"Petersen K.K.","year":"2016","unstructured":"Petersen K.K.; Siebuhr A.S.; Graven-Nielsen T.; Simonsen O.; Boesen M.; Gudbergsen H.; Karsdal M.; Bay-Jensen A.C.; Arendt-Nielsen L.; Sensitization and serological biomarkers in knee osteoarthritis patients with different degrees of synovitis. Clin J Pain 2016,32(10),841-848","journal-title":"Clin J Pain"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"105877","DOI":"10.1016\/j.mtcomm.2023.105877","volume":"35","author":"Deshmukh R.","year":"2023","unstructured":"Deshmukh R.; Rheumatoid arthritis: Pathophysiology, current therapeutic strategies and recent advances in targeted drug delivery system. Mater Today Commun 2023,35,105877","journal-title":"Mater Today Commun"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5958\/0975-6892.2020.00067.2","volume":"12","author":"Pandey M.","year":"2020","unstructured":"Pandey M.; Bajpai M.; Natural remedies for the treatment of arthritis: A review. Med. Plants -. Int J Phytomed 2020,12(4),545-554","journal-title":"Int J Phytomed"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/art.21499","volume":"54","author":"Graessler J.","year":"2006","unstructured":"Graessler J.; Graessler A.; Unger S.; Kopprasch S.; Tausche A.K.; Kuhlisch E.; Schroeder H.E.; Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006,54(1),292-300","journal-title":"Arthritis Rheum"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.addr.2013.11.014","volume":"73","author":"Delgado-Charro M.B.","year":"2014","unstructured":"Delgado-Charro M.B.; Guy R.H.; Effective use of transdermal drug delivery in children. Adv Drug Deliv Rev 2014,73,63-82","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=15","first-page":"1","volume":"4","author":"Bhowmick M.","year":"2013","unstructured":"Bhowmick M.; Sengodan, TJPG Mechanisms, kinetics and mathematical modelling of transdermal permeation-an updated review. Int J Comprehen Pharm 2013,4(6),1-4","journal-title":"Int J Comprehen Pharm"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0005-2736(97)00177-6","volume":"1368","author":"Cevc G.","year":"1998","unstructured":"Cevc G.; Gebauer D.; Stieber J.; Sch\u00e4tzlein A.; Blume G.; Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim Biophys Acta Biomembr 1998,1368(2),201-215","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"Moreland L.W.","year":"1999","unstructured":"Moreland L.W.; Schiff M.H.; Baumgartner S.W.; Tindall E.A.; Fleischmann R.M.; Bulpitt K.J.; Weaver A.L.; Keystone E.C.; Furst D.E.; Mease P.J.; Ruderman E.M.; Horwitz D.A.; Arkfeld D.G.; Garrison L.; Burge D.J.; Blosch C.M.; Lange M.L.; McDonnell N.D.; Weinblatt M.E.; Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999,130(6),478-486","journal-title":"Ann Intern Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.neuroimage.2008.08.033","volume":"43","author":"Beer J.S.","year":"2008","unstructured":"Beer J.S.; Stallen M.; Lombardo M.V.; Gonsalkorale K.; Cunningham W.A.; Sherman J.W.; The Quadruple Process model approach to examining the neural underpinnings of prejudice. Neuroimage 2008,43(4),775-783","journal-title":"Neuroimage"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.0105-2896.2009.00860.x","volume":"233","author":"Martinon F.","year":"2010","unstructured":"Martinon F.; Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 2010,233(1),218-232","journal-title":"Immunol Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1097\/HJH.0b013e32830e4945","volume":"26","author":"Men\u00e8 P.","year":"2008","unstructured":"Men\u00e8 P.; Punzo G.; Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens 2008,26(11),2085-2092","journal-title":"J Hypertens"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/ar2669","volume":"11","author":"Gabriel S.E.","year":"2009","unstructured":"Gabriel S.E.; Michaud K.; Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009,11(3),229","journal-title":"Arthritis Res Ther"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3810\/pgm.2012.11.2616","volume":"124","author":"Doghramji P.P.","year":"2012","unstructured":"Doghramji P.P.; Wortmann R.L.; Hyperuricemia and gout: new concepts in diagnosis and management. Postgrad Med 2012,124(6),98-109","journal-title":"Postgrad Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.maturitas.2018.10.012","volume":"118","author":"Robinson P.C.","year":"2018","unstructured":"Robinson P.C.; Gout \u2013 An update of aetiology, genetics, co-morbidities and management. Maturitas 2018,118,67-73","journal-title":"Maturitas"},{"key":"ref=24","first-page":"594","volume":"31","author":"Senna E.R.","year":"2004","unstructured":"Senna E.R.; De Barros A.L.; Silva E.O.; Costa I.F.; Pereira L.V.; Ciconelli R.M.; Ferraz M.B.; Prevalence of rheumatic diseases in Brazil: A study using the COPCORD approach. J Rheumatol 2004,31(3),594-597","journal-title":"J Rheumatol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"FitzGerald J.D.","year":"2020","unstructured":"FitzGerald J.D.; Dalbeth N.; Mikuls T.; Brignardello-Petersen R.; Guyatt G.; Abeles A.M.; Gelber A.C.; Harrold L.R.; Khanna D.; King C.; Levy G.; Libbey C.; Mount D.; Pillinger M.H.; Rosenthal A.; Singh J.A.; Sims J.E.; Smith B.J.; Wenger N.S.; Bae S.S.; Danve A.; Khanna P.P.; Kim S.C.; Lenert A.; Poon S.; Qasim A.; Sehra S.T.; Sharma T.S.K.; Toprover M.; Turgunbaev M.; Zeng L.; Zhang M.A.; Turner A.S.; Neogi T.; 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res 2020,72(6),744-760","journal-title":"Arthritis Care Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.15171\/apb.2018.021","volume":"8","author":"Haque T.","year":"2018","unstructured":"Haque T.; Talukder M.M.U.; Chemical enhancer: A simplistic way to modulate barrier function of the stratum corneum. Adv Pharm Bull 2018,8(2),169-179","journal-title":"Adv Pharm Bull"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jconrel.2022.09.025","volume":"351","author":"Phatale V.","year":"2022","unstructured":"Phatale V.; Vaiphei K.K.; Jha S.; Patil D.; Agrawal M.; Alexander A.; Overcoming skin barriers through advanced transdermal drug delivery approaches. J Control Release 2022,351,361-380","journal-title":"J Control Release"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejpb.2013.12.004","volume":"86","author":"Vitorino C.","year":"2014","unstructured":"Vitorino C.; Almeida A.; Sousa J.; Lamarche I.; Gobin P.; Marchand S.; Couet W.; Olivier J.C.; Pais A.; Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: In vitro vs. in vivo studies. Eur J Pharm Biopharm 2014,86(2),133-144","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4155\/tde.10.16","volume":"1","author":"Paudel K.S.","year":"2010","unstructured":"Paudel K.S.; Milewski M.; Swadley C.L.; Brogden N.K.; Ghosh P.; Stinchcomb A.L.; Challenges and opportunities in dermal\/transdermal delivery. Ther Deliv 2010,1(1),109-131","journal-title":"Ther Deliv"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12272-010-0301-7","volume":"33","author":"Subedi R.K.","year":"2010","unstructured":"Subedi R.K.; Oh S.Y.; Chun M.K.; Choi H.K.; Recent advances in transdermal drug delivery. Arch Pharm Res 2010,33(3),339-351","journal-title":"Arch Pharm Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jps.23773","volume":"103","author":"Kraft J.C.","year":"2014","unstructured":"Kraft J.C.; Freeling J.P.; Wang Z.; Ho R.J.Y.; Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 2014,103(1),29-52","journal-title":"J Pharm Sci"},{"key":"ref=32","first-page":"14","volume":"3","author":"Dua J.","year":"2012","unstructured":"Dua J.; Rana A.; Bhandari, AJIJPSR Liposome: Methods of preparation and applications. SCRIBD 2012,3,14-20","journal-title":"SCRIBD"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0168-3659(99)00222-9","volume":"65","author":"Touitou E.","year":"2000","unstructured":"Touitou E.; Dayan N.; Bergelson L.; Godin B.; Eliaz M.; Ethosomes \u2014 novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Release 2000,65(3),403-418","journal-title":"J Control Release"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v13.i3-4.30","volume":"13","author":"Cevc G.","year":"1996","unstructured":"Cevc G.; Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996,13(3-4),257-388","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4103\/0110-5558.76435","volume":"1","author":"Kuotsu K.","year":"2010","unstructured":"Kuotsu K.; Karim K.M.; Mandal A.S.; Biswas N.; Guha A.; Chatterjee S.; Behera M.; Niosome: A future of targeted drug delivery systems. J Adv Pharm Technol Res 2010,1(4),374-380","journal-title":"J Adv Pharm Technol Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2174\/1567201817666200804105416","volume":"18","author":"Gupta R.","year":"2021","unstructured":"Gupta R.; Kumar A.; Transfersomes: The ultra-deformable carrier system for non-invasive delivery of drug. Curr Drug Deliv 2021,18(4),408-420","journal-title":"Curr Drug Deliv"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/pharmaceutics14030533","volume":"14","author":"Jacob S.","year":"2022","unstructured":"Jacob S.; Nair A.B.; Shah J.; Gupta S.; Boddu S.H.S.; Sreeharsha N.; Joseph A.; Shinu P.; Morsy M.A.; Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy\u2014an overview on recent advances. Pharmaceutics 2022,14(3),533","journal-title":"Pharmaceutics"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"26777","DOI":"10.1039\/D0RA03491F","volume":"10","author":"Duan Y.","year":"2020","unstructured":"Duan Y.; Dhar A.; Patel C.; Khimani M.; Neogi S.; Sharma P.; Siva Kumar N.; Vekariya R.L.; A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Advances 2020,10(45),26777-26791","journal-title":"RSC Advances"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","volume":"116","author":"Kamaly N.","year":"2016","unstructured":"Kamaly N.; Yameen B.; Wu J.; Farokhzad O.C.; Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. Chem Rev 2016,116(4),2602-2663","journal-title":"Chem Rev"},{"key":"ref=40","first-page":"765","volume":"6","author":"Wang J.J.","year":"2011","unstructured":"Wang J.J.; Zeng Z.W.; Xiao R.Z.; Xie T.; Zhou G.L.; Zhan X.R.; Wang S.L.; Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine 2011,6,765-774","journal-title":"Int J Nanomedicine"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jconrel.2020.01.028","volume":"320","author":"Molavi F.","year":"2020","unstructured":"Molavi F.; Barzegar-Jalali M.; Hamishehkar H.; Polyester based polymeric nano and microparticles for pharmaceutical purposes: A review on formulation approaches. J Control Release 2020,320,265-282","journal-title":"J Control Release"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.biopha.2017.11.026","volume":"97","author":"Prasad M.","year":"2018","unstructured":"Prasad M.; Lambe U.P.; Brar B.; Shah I.; J, M.; Ranjan, K.; Rao, R.; Kumar, S.; Mahant, S.; Khurana, S.K.; Iqbal, H.M.N.; Dhama, K.; Misri, J.; Prasad, G. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomed Pharmacother 2018,97,1521-1537","journal-title":"Biomed Pharmacother"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","volume":"86","author":"Singh R.","year":"2009","unstructured":"Singh R.; Lillard J.W.; Jr Nanoparticle-based targeted drug delivery. Exp Mol Pathol 2009,86(3),215-223","journal-title":"Exp Mol Pathol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1021\/mp900056g","volume":"6","author":"Jain J.","year":"2009","unstructured":"Jain J.; Arora S.; Rajwade J.M.; Omray P.; Khandelwal S.; Paknikar K.M.; Silver nanoparticles in therapeutics: Development of an antimicrobial gel formulation for topical use. Mol Pharm 2009,6(5),1388-1401","journal-title":"Mol Pharm"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.nano.2005.06.004","volume":"1","author":"Koo O.M.","year":"2005","unstructured":"Koo O.M.; Rubinstein I.; Onyuksel H.; Role of nanotechnology in targeted drug delivery and imaging: A concise review. Nanomedicine 2005,1(3),193-212","journal-title":"Nanomedicine"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jconrel.2017.11.049","volume":"270","author":"Rai V.K.","year":"2018","unstructured":"Rai V.K.; Mishra N.; Yadav K.S.; Yadav N.P.; Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: Formulation development, stability issues, basic considerations and applications. J Control Release 2018,270,203-225","journal-title":"J Control Release"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"122122","DOI":"10.1016\/j.ijpharm.2022.122122","volume":"625","author":"Chen Y.","year":"2022","unstructured":"Chen Y.; Feng X.; Gold nanoparticles for skin drug delivery. Int J Pharm 2022,625,122122","journal-title":"Int J Pharm"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1039\/b806051g","volume":"38","author":"Boisselier E.","year":"2009","unstructured":"Boisselier E.; Astruc D.; Gold nanoparticles in nanomedicine: Preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev 2009,38(6),1759-1782","journal-title":"Chem Soc Rev"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.1021\/cm0508017","volume":"17","author":"Doty R.C.","year":"2005","unstructured":"Doty R.C.; Tshikhudo T.R.; Brust M.; Fernig D.G.; Extremely stable water-soluble Ag nanoparticles. Chem Mater 2005,17(18),4630-4635","journal-title":"Chem Mater"},{"key":"ref=50","first-page":"756","author":"Batrakova E.V.","year":"2006","unstructured":"Batrakova E.V.; Bronich T.K.; Vetro J.A.;  Nanoparticulates as drug carriers 2006,756","journal-title":"Nanoparticulates as drug carriers"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nantod.2012.01.002","volume":"7","author":"Owen S.C.","year":"2012","unstructured":"Owen S.C.; Chan D.P.Y.; Shoichet M.S.; Polymeric micelle stability. Nano Today 2012,7(1),53-65","journal-title":"Nano Today"},{"key":"ref=52","first-page":"142","volume":"3","author":"Tripathy S.","year":"2013","unstructured":"Tripathy S.; Das M.K.; Dendrimers and their applications as novel drug delivery carriers. J Appl Pharm Sci 2013,3(9),142-149","journal-title":"J Appl Pharm Sci"},{"key":"ref=53","first-page":"5789","volume":"9","author":"Ramasamy S.","year":"2014","unstructured":"Ramasamy S.; Bennet D.; Kim S.; Drug and bioactive molecule screening based on a bioelectrical impedance cell culture platform. Int J Nanomedicine 2014,9,5789-5809","journal-title":"Int J Nanomedicine"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2019.02.005","volume":"298","author":"Rostamabadi H.","year":"2019","unstructured":"Rostamabadi H.; Falsafi S.R.; Jafari S.M.; Nanoencapsulation of carotenoids within lipid-based nanocarriers. J Control Release 2019,298,38-67","journal-title":"J Control Release"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jddst.2019.03.006","volume":"51","author":"Harwansh R.K.","year":"2019","unstructured":"Harwansh R.K.; Deshmukh R.; Rahman M.A.; Nanoemulsion: Promising nanocarrier system for delivery of herbal bioactives. J Drug Deliv Sci Technol 2019,51,224-233","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1021\/nn102383s","volume":"5","author":"Lim J.","year":"2011","unstructured":"Lim J.; Lanni C.; Evarts E.R.; Lanni F.; Tilton R.D.; Majetich S.A.; Magnetophoresis of nanoparticles. ACS Nano 2011,5(1),217-226","journal-title":"ACS Nano"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.aca.2011.02.019","volume":"690","author":"Suwa M.","year":"2011","unstructured":"Suwa M.; Watarai H.; Magnetoanalysis of micro\/nanoparticles: A review. Anal Chim Acta 2011,690(2),137-147","journal-title":"Anal Chim Acta"},{"key":"ref=58","first-page":"1","volume":"4","author":"Dixit N.","year":"2007","unstructured":"Dixit N.; Bali V.; Baboota S.; Ahuja A.; Ali J.; Iontophoresis - an approach for controlled drug delivery: A review. Curr Drug Deliv 2007,4(1),1-10","journal-title":"Curr Drug Deliv"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0302-4598(96)05062-3","volume":"41","author":"Weaver J.C.","year":"1996","unstructured":"Weaver J.C.; Chizmadzhev Y.A.; Theory of electroporation: A review. Bioelectrochem Bioenerg 1996,41(2),135-160","journal-title":"Bioelectrochem Bioenerg"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"168","DOI":"10.5455\/aim.2011.19.168-171","volume":"19","author":"Carovac A.","year":"2011","unstructured":"Carovac A.; Smajlovic F.; Junuzovic D.; Application of ultrasound in medicine. Acta Inform Med 2011,19(3),168-171","journal-title":"Acta Inform Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.actbio.2016.06.005","volume":"41","author":"Zhu D.D.","year":"2016","unstructured":"Zhu D.D.; Wang Q.L.; Liu X.B.; Guo X.D.; Rapidly separating microneedles for transdermal drug delivery. Acta Biomater 2016,41,312-319","journal-title":"Acta Biomater"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/adt.2020.1022","volume":"19","author":"Gupta J.","year":"2021","unstructured":"Gupta J.; Gupta R.; Vanshita, Vanshita, Microneedle technology: An insight into recent advancements and future trends in drug and vaccine delivery. Assay Drug Dev Technol 2021,19(2),97-114","journal-title":"Assay Drug Dev Technol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"8419","DOI":"10.1039\/D2TB01648F","volume":"10","author":"Unver N.","year":"2022","unstructured":"Unver N.; Odabas S.; Demirel G.B.; Gul O.T.; Hollow microneedle array fabrication using a rational design to prevent skin clogging in transdermal drug delivery. J Mater Chem B Mater Biol Med 2022,10(41),8419-8431","journal-title":"J Mater Chem B Mater Biol Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1166\/jbn.2017.2474","volume":"13","author":"Hao Y.","year":"2017","unstructured":"Hao Y.; Li W.; Zhou X.; Yang F.; Qian Z.; Microneedles-based transdermal drug delivery systems: A review. J Biomed Nanotechnol 2017,13(12),1581-1597","journal-title":"J Biomed Nanotechnol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/mi12040435","volume":"12","author":"Menon I.","year":"2021","unstructured":"Menon I.; Bagwe P.; Gomes K.B.; Bajaj L.; Gala R.; Uddin M.N.; D\u2019Souza M.J.; Zughaier S.M.; Microneedles: A new generation vaccine delivery system. Micromachines 2021,12(4),435","journal-title":"Micromachines"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/phar.1788","volume":"36","author":"Wilson L.","year":"2016","unstructured":"Wilson L.; Saseen J.J.; Gouty arthritis: A review of acute management and prevention. Pharmacotherapy 2016,36(8),906-922","journal-title":"Pharmacotherapy"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","volume":"17","author":"Ahern M.J.","year":"1987","unstructured":"Ahern M.J.; Reid C.; Gordon T.P.; McCREDlE, M.; Brooks, P.M.; Jones, M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987,17(3),301-304","journal-title":"Aust N Z J Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/ard.2006.060368","volume":"66","author":"Pascual E.","year":"2007","unstructured":"Pascual E.; Sivera F.; Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007,66(8),1056-1058","journal-title":"Ann Rheum Dis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.clinthera.2014.07.017","volume":"36","author":"Dalbeth N.","year":"2014","unstructured":"Dalbeth N.; Lauterio T.J.; Wolfe H.R.; Mechanism of action of colchicine in the treatment of gout. Clin Ther 2014,36(10),1465-1479","journal-title":"Clin Ther"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1163\/156856005774415565","volume":"13","author":"Kean W.F.","year":"2005","unstructured":"Kean W.F.; Buchanan W.W.; The use of NSAIDs in rheumatic disorders 2005: A global perspective. Inflammopharmacology 2005,13(4),343-370","journal-title":"Inflammopharmacology"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1007\/s12325-019-01053-x","volume":"36","author":"Varrassi G.","year":"2019","unstructured":"Varrassi G.; Alon E.; Bagnasco M.; Lanata L.; Mayoral-Rojals V.; Paladini A.; Pergolizzi J.V.; Perrot S.; Scarpignato C.; T\u00f6lle T.; Towards an effective and safe treatment of inflammatory pain: A delphi-guided expert consensus. Adv Ther 2019,36(10),2618-2637","journal-title":"Adv Ther"},{"key":"ref=72","first-page":"831","volume":"90","author":"Hainer B.L.","year":"2014","unstructured":"Hainer B.L.; Matheson E.; Wilkes R.T.; Diagnosis, treatment, and prevention of gout. Am Fam Physician 2014,90(12),831-836","journal-title":"Am Fam Physician"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.semarthrit.2020.04.010","volume":"50","author":"Pillinger M.H.","year":"2020","unstructured":"Pillinger M.H.; Mandell B.F.; Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum 2020,50(3),S24-S30","journal-title":"Semin Arthritis Rheum"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3810\/pgm.2011.11.2505","volume":"123","author":"Lieberman J.A.","year":"2011","unstructured":"Lieberman J.A.; Treatment and prophylaxis of gout flare in the clinic: An office-based approach to gout management. Postgrad Med 2011,123(6),151-165","journal-title":"Postgrad Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejim.2020.01.001","volume":"74","author":"Brucato A.","year":"2020","unstructured":"Brucato A.; Cianci F.; Carnovale C.; Management of hyperuricemia in asymptomatic patients: A critical appraisal. Eur J Intern Med 2020,74,8-17","journal-title":"Eur J Intern Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2001732","DOI":"10.1002\/adhm.202001732","volume":"10","author":"Chen L.","year":"2021","unstructured":"Chen L.; Wang Y.; Sun L.; Yan J.; Mao H.Q.; Nanomedicine strategies for anti\u2010inflammatory treatment of noninfectious Arthritis. Adv Healthc Mater 2021,10(11),2001732","journal-title":"Adv Healthc Mater"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrd4333","volume":"13","author":"Torchilin V.P.","year":"2014","unstructured":"Torchilin V.P.; Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov 2014,13(11),813-827","journal-title":"Nat Rev Drug Discov"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"102946","DOI":"10.1016\/j.jddst.2021.102946","volume":"67","author":"Aslam H.","year":"2022","unstructured":"Aslam H.; Shukrullah S.; Naz M.Y.; Fatima H.; Hussain H.; Ullah S.; Assiri M.A.; Current and future perspectives of multifunctional magnetic nanoparticles based controlled drug delivery systems. J Drug Deliv Sci Technol 2022,67,102946","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0378-5173(00)00623-2","volume":"214","author":"Lippacher A.","year":"2001","unstructured":"Lippacher A.; M\u00fcller R.H.; M\u00e4der K.; Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm 2001,214(1-2),9-12","journal-title":"Int J Pharm"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1021\/nn301215q","volume":"7","author":"Lee S.M.","year":"2013","unstructured":"Lee S.M.; Kim H.J.; Ha Y.J.; Park Y.N.; Lee S.K.; Park Y.B.; Yoo K.H.; Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles. ACS Nano 2013,7(1),50-57","journal-title":"ACS Nano"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3831\/KPI.2019.22.029","volume":"22","author":"Kesharwani D.","year":"2019","unstructured":"Kesharwani D.; Paliwal R.; Satapathy T.; Paul S.D.; Rheumatiod Arthritis: An updated overview of latest therapy and drug delivery. J Pharmacopuncture 2019,22(4),210-224","journal-title":"J Pharmacopuncture"},{"key":"ref=82","first-page":"255","volume":"4","author":"Satya P.M.","year":"2016","unstructured":"Satya P.M.; Padmaja N.V.; Nadiya S.; Masthani S.; Satya A.K.; A review on role of nanoparticles in rheumatoid arthritis therapy. Indian J Res Pharm Biotechnol 2016,4(6),255","journal-title":"Indian J Res Pharm Biotechnol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1080\/10408444.2018.1513991","volume":"48","author":"Lansdown A.B.G.","year":"2018","unstructured":"Lansdown A.B.G.; GOLD: Human exposure and update on toxic risks. Crit Rev Toxicol 2018,48(7),596-614","journal-title":"Crit Rev Toxicol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1021\/nn500685h","volume":"8","author":"Lee H.","year":"2014","unstructured":"Lee H.; Lee M.Y.; Bhang S.H.; Kim B.S.; Kim Y.S.; Ju J.H.; Kim K.S.; Hahn S.K.; Hyaluronate-gold nanoparticle\/tocilizumab complex for the treatment of rheumatoid arthritis. ACS Nano 2014,8(5),4790-4798","journal-title":"ACS Nano"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1016\/j.bmc.2009.04.063","volume":"17","author":"Homma A.","year":"2009","unstructured":"Homma A.; Sato H.; Okamachi A.; Emura T.; Ishizawa T.; Kato T.; Matsuura T.; Sato S.; Tamura T.; Higuchi Y.; Watanabe T.; Kitamura H.; Asanuma K.; Yamazaki T.; Ikemi M.; Kitagawa H.; Morikawa T.; Ikeya H.; Maeda K.; Takahashi K.; Nohmi K.; Izutani N.; Kanda M.; Suzuki R.; Novel hyaluronic acid\u2013methotrexate conjugates for osteoarthritis treatment. Bioorg Med Chem 2009,17(13),4647-4656","journal-title":"Bioorg Med Chem"},{"key":"ref=86","first-page":"4931","volume":"9","author":"Zheng Z.","year":"2015","unstructured":"Zheng Z.; Sun Y.; Liu Z.; Zhang M.; Li C.; Cai H.; The effect of curcumin and its nanoformulation on adjuvant-induced arthritis in rats. Drug Des Devel Ther 2015,9,4931-4942","journal-title":"Drug Des Devel Ther"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1166\/jbns.2018.1525","volume":"12","author":"Sailaja A.K.","year":"2018","unstructured":"Sailaja A.K.; Lola V.S.; Formulation of mefenamic acid loaded polymeric nanoparticles for the treatment of rheumatoid arthritis. J Bionanosci 2018,12(2),177-183","journal-title":"J Bionanosci"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"121878","DOI":"10.1016\/j.ijpharm.2022.121878","volume":"624","author":"Yasamineh S.","year":"2022","unstructured":"Yasamineh S.; Yasamineh P.; Ghafouri Kalajahi H.; Gholizadeh O.; Yekanipour Z.; Afkhami H.; Eslami M.; Hossein Kheirkhah A.; Taghizadeh M.; Yazdani Y.; Dadashpour M.; A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system. Int J Pharm 2022,624,121878","journal-title":"Int J Pharm"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijpharm.2007.10.014","volume":"352","author":"Ye J.","year":"2008","unstructured":"Ye J.; Wang Q.; Zhou X.; Zhang N.; Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm 2008,352(1-2),273-279","journal-title":"Int J Pharm"},{"key":"ref=90","first-page":"6603","volume":"10","author":"Boechat A.L.","year":"2015","unstructured":"Boechat A.L.; de Oliveira C.P.; Tarrag\u00f4 A.M.; da Costa A.G.; Malheiro A.; Guterres S.S.; Pohlmann A.R.; Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model. Int J Nanomedicine 2015,10,6603-6614","journal-title":"Int J Nanomedicine"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1080\/10717544.2018.1447050","volume":"25","author":"Zhou M.","year":"2018","unstructured":"Zhou M.; Hou J.; Zhong Z.; Hao N.; Lin Y.; Li C.; Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy. Drug Deliv 2018,25(1),716-722","journal-title":"Drug Deliv"},{"key":"ref=92","author":"Sahin N.O.","year":"2007","unstructured":"Sahin N.O.;  Niosomes as Nanocarrier SystemsNanomaterials and Nanosystems for Biomedical Applications 2007","journal-title":"Niosomes as Nanocarrier SystemsNanomaterials and Nanosystems for Biomedical Applications"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1039\/D2NA00229A","volume":"4","author":"Nasra S.","year":"2022","unstructured":"Nasra S.; Bhatia D.; Kumar A.; Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment. Nanoscale Adv 2022,4(17),3479-3494","journal-title":"Nanoscale Adv"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1556-276X-8-102","volume":"8","author":"Akbarzadeh A.","year":"2013","unstructured":"Akbarzadeh A.; Rezaei-Sadabady R.; Davaran S.; Joo S.W.; Zarghami N.; Hanifehpour Y.; Samiei M.; Kouhi M.; Nejati-Koshki K.; Liposome: Classification, preparation, and applications. Nanoscale Res Lett 2013,8(1),102","journal-title":"Nanoscale Res Lett"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1021\/mp2000742","volume":"8","author":"van den Hoven J.M.","year":"2011","unstructured":"van den Hoven J.M.; Van Tomme S.R.; Metselaar J.M.; Nuijen B.; Beijnen J.H.; Storm G.; Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm 2011,8(4),1002-1015","journal-title":"Mol Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/IJN.S25310","volume":"7","author":"Prabhu P.","year":"2012","unstructured":"Prabhu P.; Shetty R.; Koland M.; Bhat V.K.; Vijayalakshmi K.K.; Nairy H.M.; Shetty N.G.; Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity. Int J Nanomedicine 2012,7,177-186","journal-title":"Int J Nanomedicine"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3109\/03009742.2015.1030448","volume":"44","author":"Gottschalk O.","year":"2015","unstructured":"Gottschalk O.; Metz P.; Dao Trong M.L.; Altenberger S.; Jansson V.; Mutschler W.; Schmitt-Sody M.; Therapeutic effect of methotrexate encapsulated in cationic liposomes (EndoMTX) in comparison to free methotrexate in an antigen-induced arthritis study in vivo. Scand J Rheumatol 2015,44(6),456-463","journal-title":"Scand J Rheumatol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/978351","volume":"2014","author":"Kapoor B.","year":"2014","unstructured":"Kapoor B.; Singh S.K.; Gulati M.; Gupta R.; Vaidya Y.; Application of liposomes in treatment of rheumatoid arthritis: quo vadis. Sci World J 2014,2014,1-17","journal-title":"Sci World J"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1208\/s12249-017-0939-2","volume":"19","author":"Ghosh S.","year":"2018","unstructured":"Ghosh S.; Mukherjee B.; Chaudhuri S.; Roy T.; Mukherjee A.; Sengupta S.; Methotrexate aspasomes against rheumatoid arthritis: Optimized hydrogel loaded liposomal formulation with in vivo evaluation in wistar rats. AAPS PharmSciTech 2018,19(3),1320-1336","journal-title":"AAPS PharmSciTech"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","volume":"75","author":"Kumari A.","year":"2010","unstructured":"Kumari A.; Yadav S.K.; Yadav S.C.; Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010,75(1),1-18","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1039\/C3RA47370H","volume":"4","author":"Ahmad Z.","year":"2014","unstructured":"Ahmad Z.; Shah A.; Siddiq M.; Kraatz H-B.; Polymeric micelles as drug delivery vehicles. RSC Advances 2014,4(33),17028-17038","journal-title":"RSC Advances"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1021\/mp300539f","volume":"10","author":"Sethi V.","year":"2013","unstructured":"Sethi V.; Rubinstein I.; Kuzmis A.; Kastrissios H.; Artwohl J.; Onyuksel H.; Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis. Mol Pharm 2013,10(2),728-738","journal-title":"Mol Pharm"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3389\/fendo.2019.00729","volume":"10","author":"Gomariz R.P.","year":"2019","unstructured":"Gomariz R.P.; Juarranz Y.; Carri\u00f3n M.; P\u00e9rez-Garc\u00eda S.; Villanueva-Romero R.; Gonz\u00e1lez-\u00c1lvaro I.; Guti\u00e9rrez-Ca\u00f1as I.; Lamana A.; Mart\u00ednez C.; An overview of VPAC receptors in rheumatoid arthritis: Biological role and clinical significance. Front Endocrinol 2019,10,729","journal-title":"Front Endocrinol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphar.2017.00460","volume":"8","author":"Li P.","year":"2017","unstructured":"Li P.; Zheng Y.; Chen X.; Drugs for autoimmune inflammatory diseases: From small molecule compounds to Anti-TNF biologics. Front Pharmacol 2017,8,460","journal-title":"Front Pharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1039\/C5SM02958A","volume":"12","author":"Gupta A.","year":"2016","unstructured":"Gupta A.; Eral H.B.; Hatton T.A.; Doyle P.S.; Nanoemulsions: Formation, properties and applications. Soft Matter 2016,12(11),2826-2841","journal-title":"Soft Matter"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jconrel.2017.03.008","volume":"252","author":"Singh Y.","year":"2017","unstructured":"Singh Y.; Meher J.G.; Raval K.; Khan F.A.; Chaurasia M.; Jain N.K.; Chourasia M.K.; Nanoemulsion: Concepts, development and applications in drug delivery. J Control Release 2017,252,28-49","journal-title":"J Control Release"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1208\/s12249-016-0667-z","volume":"18","author":"Cao M.","year":"2017","unstructured":"Cao M.; Ren L.; Chen G.; Formulation optimization and ex vivo and in vivo evaluation of celecoxib microemulsion-based gel for transdermal delivery. AAPS PharmSciTech 2017,18(6),1960-1971","journal-title":"AAPS PharmSciTech"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.msec.2015.11.041","volume":"60","author":"Zhang H.","year":"2016","unstructured":"Zhang H.; Zhai Y.; Wang J.; Zhai G.; New progress and prospects: The application of nanogel in drug delivery. Mater Sci Eng C 2016,60,560-568","journal-title":"Mater Sci Eng C"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.2147\/DDDT.S264648","volume":"14","author":"Ghasemiyeh P.","year":"2020","unstructured":"Ghasemiyeh P.; Mohammadi-Samani S.; Potential of nanoparticles as permeation enhancers and targeted delivery options for skin: Advantages and disadvantages. Drug Des Devel Ther 2020,14,3271-3289","journal-title":"Drug Des Devel Ther"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.3390\/cancers14194959","volume":"14","author":"Allegrini S.","year":"2022","unstructured":"Allegrini S.; Garcia-Gil M.; Pesi R.; Camici M.; Tozzi M.G.; The good, the bad and the new about uric acid in cancer. Cancers 2022,14(19),4959","journal-title":"Cancers"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s13346-021-00909-6","volume":"12","author":"Ramadon D.","year":"2022","unstructured":"Ramadon D.; McCrudden M.T.C.; Courtenay A.J.; Donnelly R.F.; Enhancement strategies for transdermal drug delivery systems: Current trends and applications. Drug Deliv Transl Res 2022,12(4),758-791","journal-title":"Drug Deliv Transl Res"},{"key":"ref=112","first-page":"215","volume":"114","author":"Engel B.","year":"2017","unstructured":"Engel B.; Just J.; Bleckwenn M.; Weckbecker K.; Treatment options for Gout. Dtsch Arztebl Int 2017,114(13),215-222","journal-title":"Dtsch Arztebl Int"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.msec.2018.06.030","volume":"92","author":"Ariamoghaddam A.","year":"2018","unstructured":"Ariamoghaddam A.; Ebrahimi-Hosseinzadeh B.; Hatamian-Zarmi A.; Sahraeian R.; In vivo anti-obesity efficacy of curcumin loaded nanofibers transdermal patches in high-fat diet induced obese rats. Mater Sci Eng C 2018,92,161-171","journal-title":"Mater Sci Eng C"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/foods6100092","volume":"6","author":"Hewlings S.","year":"2017","unstructured":"Hewlings S.; Kalman D.; Curcumin: A review of its effects on human health. Foods 2017,6(10),92","journal-title":"Foods"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/10717544.2018.1559258","volume":"26","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Zhang N.; Song H.; Li H.; Wen J.; Tan X.; Zheng W.; Design, characterization and comparison of transdermal delivery of colchicine via borneol-chemically-modified and borneol-physically-modified ethosome. Drug Deliv 2019,26(1),70-77","journal-title":"Drug Deliv"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1159\/000525494","volume":"107","author":"Samadi F.","year":"2022","unstructured":"Samadi F.; Kahrizi M.S.; Heydari F.; Arefnezhad R.; Roghani-Shahraki H.; Mokhtari Ardekani A.; Rezaei-Tazangi F.; Quercetin and osteoarthritis: A mechanistic review on the present documents. Pharmacology 2022,107(9-10),464-471","journal-title":"Pharmacology"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"12754","DOI":"10.3390\/ijms222312754","volume":"22","author":"Li Z.","year":"2021","unstructured":"Li Z.; Fang X.; Yu D.; Transdermal drug delivery systems and their use in obesity treatment. Int J Mol Sci 2021,22(23),12754","journal-title":"Int J Mol Sci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.mcna.2019.10.007","volume":"104","author":"Abramoff B.","year":"2020","unstructured":"Abramoff B.; Caldera F.E.;  Osteoarthritis Med Clin North Am 2020,104(2),293-311","journal-title":"Osteoarthritis Med Clin North Am"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2105\/AJPH.2017.304179","volume":"108","author":"Park J.","year":"2018","unstructured":"Park J.; Mendy A.; Vieira E.R.; Various types of arthritis in the united states: Prevalence and age-related trends from 1999 to 2014. Am J Public Health 2018,108(2),256-258","journal-title":"Am J Public Health"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"Smolen J.S.","year":"2020","unstructured":"Smolen J.S.; Landew\u00e9 R.B.M.; Bijlsma J.W.J.; Burmester G.R.; Dougados M.; Kerschbaumer A.; McInnes I.B.; Sepriano A.; van Vollenhoven R.F.; de Wit M.; Aletaha D.; Aringer M.; Askling J.; Balsa A.; Boers M.; den Broeder A.A.; Buch M.H.; Buttgereit F.; Caporali R.; Cardiel M.H.; De Cock D.; Codreanu C.; Cutolo M.; Edwards C.J.; van Eijk-Hustings Y.; Emery P.; Finckh A.; Gossec L.; Gottenberg J.E.; Hetland M.L.; Huizinga T.W.J.; Koloumas M.; Li Z.; Mariette X.; M\u00fcller-Ladner U.; Mysler E.F.; da Silva J.A.P.; Po\u00f3r G.; Pope J.E.; Rubbert-Roth A.; Ruyssen-Witrand A.; Saag K.G.; Strangfeld A.; Takeuchi T.; Voshaar M.; Westhovens R.; van der Heijde D.; EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020,79(6),685-699","journal-title":"Ann Rheum Dis"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1592\/phco.30.6.594","volume":"30","author":"Love B.L.","year":"2010","unstructured":"Love B.L.; Barrons R.; Veverka A.; Snider K.M.; Urate-lowering therapy for gout: Focus on febuxostat. Pharmacotherapy 2010,30(6),594-608","journal-title":"Pharmacotherapy"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"Khanna D.","year":"2012","unstructured":"Khanna D.; Fitzgerald J.D.; Khanna P.P.; Bae S.; Singh M.K.; Neogi T.; Pillinger M.H.; Merill J.; Lee S.; Prakash S.; Kaldas M.; Gogia M.; Perez-Ruiz F.; Taylor W.; Liot\u00e9 F.; Choi H.; Singh J.A.; Dalbeth N.; Kaplan S.; Niyyar V.; Jones D.; Yarows S.A.; Roessler B.; Kerr G.; King C.; Levy G.; Furst D.E.; Edwards N.L.; Mandell B.; Schumacher H.R.; Robbins M.; Wenger N.; Terkeltaub R.; 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012,64(10),1431-1446","journal-title":"Arthritis Care Res"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/ard.2004.034165","volume":"64","author":"Mease P.J.","year":"2005","unstructured":"Mease P.J.; Antoni C.E.; Gladman D.D.; Taylor W.J.; Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005,64(Suppl. 2),49-54","journal-title":"Ann Rheum Dis"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13075-021-02568-x","volume":"23","author":"Cipolletta E.","year":"2021","unstructured":"Cipolletta E.; Di Battista J.; Di Carlo M.; Di Matteo A.; Salaffi F.; Grassi W.; Filippucci E.; Sonographic estimation of monosodium urate burden predicts the fulfillment of the 2016 remission criteria for gout: A 12-month study. Arthritis Res Ther 2021,23(1),185","journal-title":"Arthritis Res Ther"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","volume":"13","author":"So A.K.","year":"2017","unstructured":"So A.K.; Martinon F.; Inflammation in gout: Mechanisms and therapeutic targets. Nat Rev Rheumatol 2017,13(11),639-647","journal-title":"Nat Rev Rheumatol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","volume":"2","author":"Genovese M.C.","year":"2020","unstructured":"Genovese M.C.; Smolen J.S.; Takeuchi T.; Burmester G.; Brinker D.; Rooney T.P.; Zhong J.; Daojun M.; Saifan C.; Cardoso A.; Issa M.; Wu W-S.; Winthrop K.L.; Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: An updated integrated safety analysis. Lancet Rheumatol 2020,2(6),e347-e357","journal-title":"Lancet Rheumatol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejps.2018.03.020","volume":"118","author":"Santos L.F.","year":"2018","unstructured":"Santos L.F.; Correia I.J.; Silva A.S.; Mano J.F.; Biomaterials for drug delivery patches. Eur J Pharm Sci 2018,118,49-66","journal-title":"Eur J Pharm Sci"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"rkz007","DOI":"10.1093\/rap\/rkz007","volume":"3","author":"Papadopoulos C.G.","year":"2019","unstructured":"Papadopoulos C.G.; Gartzonikas I.K.; Pappa T.K.; Markatseli T.E.; Migkos M.P.; Voulgari P.V.; Drosos A.A.; Eight-year survival study of first-line tumour necrosis factor \u03b1 inhibitors in rheumatoid arthritis: Real-world data from a university centre registry. Rheumatol Adv Pract 2019,3(1),rkz007","journal-title":"Rheumatol Adv Pract"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"105028","DOI":"10.1016\/j.chemphyslip.2020.105028","volume":"234","author":"Mahmood A.","year":"2021","unstructured":"Mahmood A.; Rapalli V.K.; Waghule T.; Gorantla S.; Singhvi G.; Luliconazole loaded lyotropic liquid crystalline nanoparticles for topical delivery: QbD driven optimization, in vitro characterization and dermatokinetic assessment. Chem Phys Lipids 2021,234,105028","journal-title":"Chem Phys Lipids"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"e1778","DOI":"10.1002\/wnan.1778","volume":"14","author":"Shang H.","year":"2022","unstructured":"Shang H.; Younas A.; Zhang N.; Recent advances on transdermal delivery systems for the treatment of arthritic injuries: From classical treatment to nanomedicines. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2022,14(3),e1778","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"153387","DOI":"10.1016\/j.tox.2022.153387","volume":"483","author":"Zhang M.","year":"2023","unstructured":"Zhang M.; Cui R.; Zhou Y.; Ma Y.; Jin Y.; Gou X.; Yang J.; Wu X.; Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. Toxicology 2023,483,153387","journal-title":"Toxicology"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.3390\/ijms23063188","volume":"23","author":"Gherghina M.E.","year":"2022","unstructured":"Gherghina M.E.; Peride I.; Tiglis M.; Neagu T.P.; Niculae A.; Checherita I.A.; Uric acid and oxidative stress\u2014relationship with cardiovascular, metabolic, and renal impairment. Int J Mol Sci 2022,23(6),3188","journal-title":"Int J Mol Sci"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.2147\/IJN.S138267","volume":"12","author":"Hussain A.","year":"2017","unstructured":"Hussain A.; Singh S.; Sharma D.; Webster T.; Shafaat K.; Faruk A.; Elastic liposomes as novel carriers: Recent advances in drug delivery. Int J Nanomedicine 2017,12,5087-5108","journal-title":"Int J Nanomedicine"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/RRTD.S50370","volume":"2015","author":"Romero E.L.","year":"2015","unstructured":"Romero E.L.; Morilla M.J.; Ultradeformable phospholipid vesicles as a drug delivery system: A review. Research and Reports in Transdermal Drug Delivery 2015,2015,55-69","journal-title":"Research and Reports in Transdermal Drug Delivery"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"102355","DOI":"10.1016\/j.jddst.2021.102355","volume":"62","author":"Chaturvedi S.","year":"2021","unstructured":"Chaturvedi S.; Garg A.; An insight of techniques for the assessment of permeation flux across the skin for optimization of topical and transdermal drug delivery systems. J Drug Deliv Sci Technol 2021,62,102355","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/jrptps.JRPTPS_64_20","volume":"10","author":"Chaurasiya C.","year":"2021","unstructured":"Chaurasiya C.; Gupta J.; Kumar S.; Herbal nanoemulsion in topical drug delivery and skin disorders: Green approach. J Rep Pharm Sci 2021,10(2),171-181","journal-title":"J Rep Pharm Sci"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666230606143827","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/217713\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666230606143827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T12:57:12Z","timestamp":1698843432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/217713\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201024666230606143827","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}